Linked Life Data

8281711

Source:http://linkedlifedata.com/resource/pubmed/id/8281711

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-2-14
pubmed:abstractText
CA 549 is a new mucinous circulating tumor marker recognized by two monoclonal antibodies (BC4E549 and BC4N154) recently proposed for breast cancer. In this report we compared the levels of CA 549 and CA 15.3, the best known biomarker for breast cancer nowadays, in 68 sieric and 59 cytosolic samples. Serum samples came from 59 breast patients (24 with primary disease = M-, 18 with systemic disease = M+, 17 with no evidence of disease after surgery = NED) and 9 women with benign breast disease = BBD. The cytosols were prepared from primary breast carcinomas according to the method used for hormonal receptors. At first we evaluated the analytical performance of the immunoradiometric assay for CA 549 (Hybri-BREScan, Hybritech) and its applicability to the cytosolic determination. Using a cut-off value of 12 U/mL for CA 549 and 28 U/mL for CA 15.3 serum levels, we obtained the following percentages of positivities: M- = 21%; M+ = 83%; NED = 0%; BBD = 22% for CA 549 and M- = 33%; M+ = 89%; NED = 18%; BBD = 22% for CA 15.3. CA 549 gave information concordant with CA 15.3 in a high percentage of cases both in sera and in cytosols, but the clinical relevance of cytosolic determination remains to be investigated. Since serum CA 549 showed an adequate sensitivity in M+ patients only, it may be proposed in the follow-up to confirm CA 15.3 abnormal values or as an alternative to it.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0390-6663
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
264-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Serum and cytosolic levels of CA549 in breast cancer patients.
pubmed:affiliation
RIA Laboratory, Oncology Institute of Bari, Italy.
pubmed:publicationType
Journal Article, Comparative Study